X

Category: R&D

2026 02 20

R&D

Scandinavian Biopharma

Scandinavian Biopharma Announces Publication of ETVAX® Phase 2b Data in The Lancet Infectious Diseases and Confirms Phase 3 Readiness

Scandinavian Biopharma today announces that the comprehensive results from its Phase 2b trial of ETVAX®, the lead oral vaccine candidate against enterotoxigenic Escherichia coli (ETEC), have been published in The Lancet Infectious Diseases, one of the world’s foremost peer-reviewed medical journals. The peer-reviewed publication provides detailed analysis of the trial’s safety, immunogenicity, and efficacy outcomes […]

2023 08 14

R&D

Scandinavian Biopharma

Join us! We are hiring a CMC Project Lead

We are looking for a senior project manager with experience and interest in leading complex pharmaceutical manufacturing and development projects from phase III to commercialization. We have an exciting journey ahead of us and we hope you want to join us on this journey! For more information about the role as CMC Project Lead click […]

2023 06 01

R&D

Scandinavian Biopharma

Scandinavian Biopharma welcomes Christine Hägglund to the position as VP CMC Development

Scandinavian Biopharma is pleased to inform that Christine Hägglund has been recruited as Scandinavian Biopharmas VP CMC Development. Christine holds a PhD in Biochemistry and has almost 20 years of experience in drug development of biological pharmaceuticals. Most recently, she comes from the position of Director of Analytical Science & Technology at Sobi. “I really […]

2023 03 10

R&D

Scandinavian Biopharma

Join us! We are hiring both a Senior Scientist and a Scientist

Join us when we are expanding. We are now looking for both a Senior Scientist and a Scientist with experience and interest in drug development in the late clinical phase.  Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, […]

2022 11 14

R&D

Scandinavian Biopharma

Scandinavian Biopharma has successfully completed the enrolment of their large Phase IIb trial in The Gambia

We are proud to announce that all participants have received the third and final vaccination dose in our large randomized, placebo-controlled, and double-blind phase IIb study in The Gambia. The study started in 2021 and is part of the late phase development program in Africa for Scandinavian Biopharma’s vaccine candidate, ETVAX®, against Enterotoxigenic Escherichia coli […]